Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response.

Cuevas JM, Torres-Puente M, Jiménez-Hernández N, Bracho MA, García-Robles I, Carnicer F, Olmo JD, Ortega E, Moya A, González-Candelas F.

J Viral Hepat. 2008 Aug;15(8):578-90. doi: 10.1111/j.1365-2893.2008.00991.x. Epub 2008 May 4.

PMID:
18466261
2.

Genetic variability in hepatitis C virus and its role in antiviral treatment response.

Torres-Puente M, Cuevas JM, Jiménez-Hernández N, Bracho MA, García-Robles I, Wrobel B, Carnicer F, Del Olmo J, Ortega E, Moya A, González-Candelas F.

J Viral Hepat. 2008 Mar;15(3):188-99. doi: 10.1111/j.1365-2893.2007.00929.x.

PMID:
18233992
3.

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.

Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, Vieux C, Trepo C, Zoulim F.

J Med Virol. 2004 Sep;74(1):41-53.

PMID:
15258967
4.

Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.

Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R, Quarleri J.

Antiviral Res. 2012 Aug;95(2):72-81. doi: 10.1016/j.antiviral.2012.05.015. Epub 2012 Jun 7.

PMID:
22683884
5.

The role of positive selection in hepatitis C virus.

Cuevas JM, Gonzalez M, Torres-Puente M, Jiménez-Hernández N, Bracho MA, García-Robles I, González-Candelas F, Moya A.

Infect Genet Evol. 2009 Sep;9(5):860-6. doi: 10.1016/j.meegid.2009.05.007. Epub 2009 May 20.

PMID:
19463971
6.

NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.

Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, Ben Mami N, Triki H, Chouchane L.

J Med Virol. 2009 Dec;81(12):2021-8. doi: 10.1002/jmv.21641.

PMID:
19856481
7.

Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.

Sarrazin C, Bruckner M, Herrmann E, Rüster B, Bruch K, Roth WK, Zeuzem S.

Virology. 2001 Oct 10;289(1):150-63.

8.

Variations in the viral NS5B region in Japanese patients with chronic hepatitis C virus genotype 1b infection. No specific amino acid substitution was identified as determinants of treatment response to interferon/ribavirin combination therapy.

Sugihara K, Orito E, Tanaka Y, Kato T, Lau JY, Ohno T, Hayashi K, Ogino M, Hirashima N, Sakakibara K, Mizuno Y, Kato H, Suzuki S, Ueda R, Mizokami M.

Intervirology. 2006;49(6):319-26. Epub 2006 Aug 21.

PMID:
16926544
9.

Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.

Muñoz de Rueda P, Casado J, Patón R, Quintero D, Palacios A, Gila A, Quiles R, León J, Ruiz-Extremera A, Salmerón J.

J Virol. 2008 Jul;82(13):6644-53. doi: 10.1128/JVI.02231-07. Epub 2008 Apr 30.

10.

Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.

Bolcic F, Sede M, Moretti F, Westergaard G, Vazquez M, Laufer N, Quarleri J.

Arch Virol. 2012 Apr;157(4):703-11. doi: 10.1007/s00705-012-1230-1. Epub 2012 Jan 22.

PMID:
22270759
11.

HCV genetic elements determining the early response to peginterferon and ribavirin therapy.

Enomoto N, Maekawa S.

Intervirology. 2010;53(1):66-9. doi: 10.1159/000252787. Epub 2010 Jan 5.

PMID:
20068344
12.

Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.

Querenghi F, Yu Q, Billaud G, Maertens G, Trépo C, Zoulim F.

J Viral Hepat. 2001 Mar;8(2):120-31.

PMID:
11264732
13.

Is investigation of hepatitis C virus NS5A gene heterogeneity a tool for predicting long-lasting response to interferon therapy in patients with HCV-1b chronic hepatitis?

Squadrito G, Raffa G, Restuccia T, Pollicino T, Brancatelli S, Raimondo G.

J Viral Hepat. 2002 Sep;9(5):360-9.

PMID:
12225331
14.

Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase.

Ward CL, Dev A, Rigby S, Symonds WT, Patel K, Zekry A, Pawlotsky JM, McHutchison JG.

J Viral Hepat. 2008 Aug;15(8):571-7. doi: 10.1111/j.1365-2893.2008.00980.x. Epub 2008 Mar 24.

PMID:
18363671
15.

[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin].

Veillon P, Payan C, Gaudy C, Goudeau A, Lunel F.

Pathol Biol (Paris). 2004 Nov;52(9):505-10. French.

PMID:
15531113
16.

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.

El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H.

Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.

17.

Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.

Malta Fde M, Medeiros-Filho JE, Azevedo RS, Gonçalves L, Silva LC, Carrilho FJ, Pinho JR.

Mem Inst Oswaldo Cruz. 2010 Feb;105(1):92-8.

18.
19.

Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.

Gerotto M, Sullivan DG, Polyak SJ, Chemello L, Cavalletto L, Pontisso P, Alberti A, Gretch DR.

J Virol. 1999 Sep;73(9):7241-7.

20.

Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.

Alhamlan FS, Al-Ahdal MN, Khalaf NZ, Abdo AA, Sanai FM, Al-Ashgar HI, Elhefnawi M, Zaid A, Al-Qahtani AA.

J Med Virol. 2014 Feb;86(2):224-34. doi: 10.1002/jmv.23823. Epub 2013 Oct 28.

PMID:
24166351

Supplemental Content

Support Center